ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more
ABERA BIOSCIENCE AB (8WK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ABERA BIOSCIENCE AB - Net Assets Trend (None–None)
This chart illustrates how ABERA BIOSCIENCE AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ABERA BIOSCIENCE AB (None–None)
The table below shows the annual net assets of ABERA BIOSCIENCE AB from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ABERA BIOSCIENCE AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ABERA BIOSCIENCE AB Competitors by Market Cap
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taiwan Enterprise(Cayman)Co
TW:5906
|
$9.77 Million |
|
Selangor Dredging Bhd
KLSE:2224
|
$9.77 Million |
|
Investeringsselskabet Luxor A/S
CO:LUXOR-B
|
$9.78 Million |
|
RE Royalties Ltd
OTCQX:RROYF
|
$9.78 Million |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
$9.77 Million |
|
Interwood-Xylemporia A.T.E.N.E.
AT:XYLEK
|
$9.77 Million |
|
Catskill Hudson Bancorp Inc
PINK:CSKL
|
$9.77 Million |
|
M & A EQUITY HOLDINGS BERHAD
KLSE:7082
|
$9.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABERA BIOSCIENCE AB's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ABERA BIOSCIENCE AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ABERA BIOSCIENCE AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ABERA BIOSCIENCE AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABERA BIOSCIENCE AB (8WK) | €- | N/A | N/A | $9.77 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |